We propose that the TheraVac regimen promoted activation and homing of tDCs to LN for the induction of specific immunity against CT26, which led to the eradication of CT26 tumors as well as resistance to re-challenge with CT26 tumor inoculation. The gene discussed is DDX53; the disease is neoplasm.